A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Abiraterone (Primary) ; Olaparib (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 08 Feb 2017 Planned number of patients changed from 10 to 70.
- 13 Jan 2017 Planned number of patients changed from 70 to 10.